PubMed · 1985 · 32 citations · 27 references
MedicineEndocrinologyOncologyBreast OncologyEndocrine OncologyHormone BiochemistryBreast SurgeryEndocrine Tumor PrognosisHormone ReceptorsBreast Cancer PrognosisEstrogen Receptor StatusHormone Receptor - Positive Breast CancerProgesterone Receptor StatusProgesterone ReceptorsProlactin ReceptorsRecurrenceRecurrence-free Survival
Hormone receptors for estrogen (ER), progesterone (PGR) and prolactin (PRL-R) were measured in primary breast cancer tissues obtained from 214 patients at radical mastectomy. The patients were followed up at intervals of one to three months to examine the relationship between hormone receptor status and prognosis. ER status was related to PGR status but not to PRL-R status. PRL-R was more frequently detectable in pathologic stage 3 than in stage 1 & 2 (22% vs. 10%, P less than 0.05) whereas ER and PGR were not different between stage 1 & 2 and stage 3 groups. The influence of receptor status on prognosis was analyzed in 164 patients of stage 1 & 2 by means of the actuarial life table technique. The recurrence-free interval was not related to ER, PGR or PRL-R status. The ER-positive group was associated with significantly prolonged survival compared with that of ER-negative patients at 42 to 51 months after surgery. PRL-R positive patients had a significantly worse survival than the PRL-R negative group (P less than 0.05). These findings indicate that receptor status may provide useful prognostic information in patients with early breast cancer and that the lactogenic hormone may play an unfavorable role in relation to the prognosis of human breast cancer.
27
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
E. A. Gehan · Biometrika · 1965 · 3.4K citations
The value of estrogen and progesterone receptors in the treatment of breast cancer
C. Kent Osborne, Michael G. Yochmowitz, William A. Knight et al. · Cancer · 1980 · 725 citations · Full text
Medicine, Endocrinology, Oncology +17
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.
William A. Knight, Robert B. Livingston, E Gregory et al. · PubMed · 1977 · 706 citations
Medicine, Endocrinology, Oncology +16